Novel Bispecific CAR-T Cells Against Hematological Cancers

Dr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some [...]

ProMab Bispecific Antibody Webinar

Interested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a webinar encompassing our Bispecific Antibody [...]

ProMab CAR-T Webinar

ProMab Biotechnologies is the world’s first CRO committed to improving human health with a focus on immunotherapy, specifically [...]

ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial

ProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and [...]

Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA

BERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies [...]

Products & Custom Orders for 2019 Novel Coronavirus Research

The 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread [...]

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

ProMab has recently had our work published in JoVE on the real-time cytotoxicity assay (RTCA) that we use [...]

NantKwest Signs Worldwide License Agreement with ProMab

Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option [...]

CAR-TCR Summit 2019

CAR-TCR Summit 2019 Come visit the ProMab team and learn about our new products & services Booth #50 [...]

ASCO Annual Meeting 2019

ASCO Annual Meeting 2019 Come visit the ProMab team and learn about our new products & services Booth [...]